PRNB News and Press, Principia Biopharma Inc. From 07/16/20

Gainers:  InnerWorkings (NASDAQ: INWK ) +117% . More news on: InnerWorkings, Inc., Heat Biologics, Inc., Boxlight Corporation, Stocks on the move, , Read more ...

The first patient has been enrolled in Sanofi’s (NASDAQ: SNY ) Phase 3 clinical trial of partner Principia Biopharma's (NASDAQ: PRNB ) SAR442168 in patients with relapsing multiple sclerosis. More news on: Sanofi, Principia Biopharma Inc., Healthcare stocks n...

SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that the first patient has been enrolled in its partner Sanofi’...

Principia Biopharma (NASDAQ: PRNB ) announces positive results from Part B of a Phase 2 clinical trial, BELIEVE-PV , evaluating oral BTK inhibitor rilzabrutinib in patients with pemphigus , a group of rare autoimmune disorders characterized by blisters or sores on the skin. The data were...

Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nas...

Principia Biopharma ( PRNB +2.9% )  announces positive data on durability of response from an ongoing Phase 1/2 trial of its investigational treatment, rilzabrutinib at the European Hematology Association. More news on: Principia Biopharma Inc., Healthcare stocks news, Read mor...

Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses Principia to initiate pivotal Phase 3 trial in ITP SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (N...

SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced that it will host a virtual analyst event to discuss Principia’...

SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced upcoming presentations at the European Hematology Association (EHA) an...

SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced an upcoming full data set presentation from the Phase 2 Part B pemphig...